AI-LAB Federated Learning: A Leap Forward for Radiology AI Development

AI-LAB Federated Learning: Radiologists can now register their practices to take part in the next-generation American College of Radiology Data Science Institute® artificial intelligence (AI) federated learning program hosted on the AI-LAB™ platform.

With AI-Lab federated learning, registered sites soon can participate in multi-site algorithm creation while allowing their data to remain safely on their own servers.

These sites will have access to both the community-created models and anonymized performance benchmarks so that they can understand performance of the algorithm produced by the greater clinical community to one that is fine-tuned to their own site’s data. This process will help them tune their own AI implementations to meet clinical needs.

“We as radiologists must take advantage of the new AI-LAB capabilities and leverage emerging opportunities to provide better patient care,” said Bibb Allen, MD, FACR, ACR Data Science Institute Chief Medical Officer. “The AI-LAB can allow radiologists to access resources to help them develop skills necessary to practice integrated diagnostics, become better physicians, and enhance the value we bring to patients and health systems.”

The AI-LAB process empowers radiologists to participate in AI creation, evaluation and validation, and meet coming responsibilities, requirements and opportunities in a future where AI will increasingly be used in daily practice.

“Radiologists must prepare to serve as the imaging AI experts, gatekeepers of which AI technologies are purchased by their practices, and monitors of AI performance in patient care,” Keith J. Dreyer, DO, PhD, FACR, ACR Data Science Institute Chief Science Officer. “Not doing so is to risk patient safety and algorithm effectiveness. The new AI-LAB™ can help radiologists prepare for tomorrow’s reality.”

Get more information on taking part in AI-LAB™ federated learning.

Hot this week

Cartessa Aesthetics Partners with Classys to Bring EVERESSE to the U.S. Market

Classys, which is listed on the KOSDAQ, is one of South Korea's most distinguished aesthetic technology manufacturers, with devices distributed in 80+ markets globally. This partnership marks Classys's official entry into the American marketplace, with Cartessa Aesthetics as the exclusive distributor for EVERESSE, launched under the Volnewmer brand in current global markets.

Stryker Launches Next-Generation of SurgiCount+

Now integrated with Stryker's Triton technology, SurgiCount+ addresses two key challenges: retained surgical sponges and blood loss assessment. Integrating these previously separate digital solutions provides the added benefit of a more efficient, streamlined workflow for hospitals notes Stryker.

Nevro Receives CE Mark In Europe for It’s HFX iQ™ Spinal Cord Stimulation System

Nevro notes HFX iQ is the first and only SCS system with artificial intelligence (AI) technology that combines high-frequency (10 kHz) therapy built on landmark evidence that uses ongoing cloud data insights to deliver personalized pain relief

Recor Medical Reports: CMS Grants Distinct TPT Device Code and Category to Recor Medical for Ultrasound Renal Denervation

The approval of TPT offers incremental reimbursement payments for outpatient procedures performed with ultrasound renal denervation for Medicare fee-for-service beneficiaries. It becomes effective January 1, 2025, and is expected to remain effective for up to three years notes Recor Medical.

Jupiter Endovascular Reports | 1st U.S. Patient Treated with Jupiter Shape-shifting Thrombectomy Device

“Navigation challenges during endovascular procedures are often underappreciated and have led to under-adoption of life-saving procedures, such as pulmonary embolectomy. We have purpose-built our Endoportal Control technology to solve these issues and make important endovascular procedures accessible to more clinicians and their patients who can benefit from them,” said Carl J. St. Bernard, Jupiter Endovascular CEO. “This first case in the U.S. could not have gone better, and appears to validate the safety and performance we are seeing in our currently-enrolling European SPIRARE I study.”